Stay informed, stay ahead.
A tiny retinal implant is giving new hope to people who have lost their central vision due to advanced macular disease. In a recent clinical trial, the micro-device — no bigger than a grain of rice — helped many patients read again after years of blindness. The implant was tested on patients with geographic atrophy,…
Novartis said its cancer drug Pluvicto has reduced the risk of disease progression or death by 28% in men with an advanced form of prostate cancer. The findings come from a large Phase III clinical trial. The study focused on men with PSMA-positive metastatic hormone-sensitive prostate cancer. These patients received Pluvicto along with standard hormone-based…
Novartis has announced strong results for its drug Fabhalta (iptacopan). The treatment slowed the progression of IgA nephropathy, a rare and serious kidney disease, in a major clinical trial. In the Phase III study, patients taking Fabhalta had a much slower loss of kidney function compared to those on placebo. The drug improved the eGFR…
